Apocynin is Not an Inhibitor of Vascular NADPH Oxidases but an Antioxidant
Overview
Authors
Affiliations
A large body of literature suggest that vascular reduced nicotinamide-adenine dinucleotide phosphate (NADPH) oxidases are important sources of reactive oxygen species. Many studies, however, relied on data obtained with the inhibitor apocynin (4'-hydroxy-3'methoxyacetophenone). Because the mode of action of apocynin, however, is elusive, we determined its mechanism of inhibition on vascular NADPH oxidases. In HEK293 cells overexpressing NADPH oxidase isoforms (Nox1, Nox2, or Nox4), apocynin failed to inhibit superoxide anion generation detected by lucigenin chemiluminescence. In contrast, apocynin interfered with the detection of reactive oxygen species in assay systems selective for hydrogen peroxide or hydroxyl radicals. Importantly, apocynin interfered directly with the detection of peroxides but not superoxide, if generated by xanthine/xanthine oxidase or nonenzymatic systems. In leukocytes, apocynin is a prodrug that is activated by myeloperoxidase, a process that results in the formation of apocynin dimers. Endothelial cells and smooth muscle cells failed to form these dimers and, therefore, are not able to activate apocynin. Dimer formation was, however, observed in Nox-overexpressing HEK293 cells when myeloperoxidase was supplemented. As a consequence, apocynin should only inhibit NADPH oxidase in leukocytes, whereas in vascular cells, the compound could act as an antioxidant. Indeed, in vascular smooth muscle cells, the activation of the redox-sensitive kinases p38-mitogen-activate protein kinase, Akt, and extracellular signal-regulated kinase 1/2 by hydrogen peroxide and by the intracellular radical generator menadione was prevented in the presence of apocynin. These observations indicate that apocynin predominantly acts as an antioxidant in endothelial cells and vascular smooth muscle cells and should not be used as an NADPH oxidase inhibitor in vascular systems.
NADPH Oxidase 3: Beyond the Inner Ear.
Herb M Antioxidants (Basel). 2024; 13(2).
PMID: 38397817 PMC: 10886416. DOI: 10.3390/antiox13020219.
Transforming growth factor-β receptors: versatile mechanisms of ligand activation.
Chia Z, Cao Y, Little P, Kamato D Acta Pharmacol Sin. 2024; 45(7):1337-1348.
PMID: 38351317 PMC: 11192764. DOI: 10.1038/s41401-024-01235-6.
NADPH oxidase 4 (NOX4) as a biomarker and therapeutic target in neurodegenerative diseases.
Boonpraman N, Yi S Neural Regen Res. 2024; 19(9):1961-1966.
PMID: 38227522 PMC: 11040313. DOI: 10.4103/1673-5374.390973.
In vitro cadmium exposure induces structural damage and endothelial dysfunction in female rat aorta.
Mulher L, Simoes R, Rossi K, Schereider I, Silva Nascimento C, Avila R Biometals. 2023; 36(6):1405-1420.
PMID: 37651061 DOI: 10.1007/s10534-023-00526-5.
NADPH Oxidases: From Molecular Mechanisms to Current Inhibitors.
Cipriano A, Viviano M, Feoli A, Milite C, Sarno G, Castellano S J Med Chem. 2023; 66(17):11632-11655.
PMID: 37650225 PMC: 10510401. DOI: 10.1021/acs.jmedchem.3c00770.